Despite concerns of severe drug-induced haemolysis in at-risk patients, point-of-care G6PD testing is often unavailable in malaria-endemic areas and most national malaria programmes recommend low total dose primaquine (3·5 mg/kg) administered during 14 days to reduce the risk of haemolysis.4 This evidence concerns the gene G6PD and malaria.